CBS 2019
CBSMD教育中心
中 文

Pulmonary Hypertension

Abstract

Recommended Article

Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature Update on chronic thromboembolic pulmonary hypertension Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension) Treatment Effects of Pulmonary Artery Denervation for Pulmonary Arterial Hypertension Stratified by REVEAL Risk Score: Results from PADN-CFDA Trial rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling Will Pulmonary Artery Denervation Really Have a Place in the Armamentarium of the Pulmonary Hypertension Specialist? Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function

JOURNAL: Article Link

南京市第一医院心血管内科为多名复杂性肺高压患者实施肺血管介入治疗

qiaomingyue Keywords: 近年来,肺动脉高压在病理机制、诊断、风险评估及治疗等方面有诸多新进展,治疗策略不断更新,交感神经学说在肺动脉高压发生及发展中起着重要作用。经皮肺动脉去神经术(percutaneous pulmonary artery denervation,PADN)由陈绍良教授创新发明并成功开展后,越来越多的研究证据均显示其良好的疗效及广阔的前景,随着这一技术在全球的普及,肺动脉高压的治疗已经迈入在靶向药物治疗基础上的介入治疗新时代。

网站资料更新中...